Markets:

Overview

News

Currencies

International

Treasuries

uniQure N.V. - Ordinary Shares (NQ:QURE)

27.51 -0.12 (-0.43%)

Streaming Delayed Price Updated: 1:00 PM EST, Nov 28, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about uniQure N.V. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares

September 29, 2025

From uniQure Inc.

Via GlobeNewswire

Benzinga Bulls And Bears: Oracle, Costco, NIO — And Wall Street Snaps Its Slide ↗

September 27, 2025

Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.

Via Benzinga

uniQure Announces Pricing of Upsized $300 Million Public Offering

September 25, 2025

From uniQure Inc.

Via GlobeNewswire

UniQure Stock's 248% Blastoff Was Just The Start — Ask Wall Street ↗

September 25, 2025

UniQure NV (NASDAQ: QURE) just staged one of biotech's wildest rides of the year, soaring 248% in a single session after unveiling successful trial results for its experimental Huntington's disease...

Via Benzinga

CrowdStrike To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Thursday ↗

September 25, 2025

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

uniQure Stock Jumps On Positive News, But Risks Remain ↗

September 25, 2025

uniQure (NASDAQ: QURE) has been one of the most eye-catching movers in recent sessions. The stock surged ~250% this Wednesday after reports that the company's gene therapy showed positive results in...

Via Benzinga

Wall Street Pauses AI Frenzy as Oracle Seeks $15B in Fresh Funding ↗

September 25, 2025

After weeks of record highs fueled by AI optimism, U.S. stocks cooled for a second straight day. Oracle’s massive debt raise and divergent moves in chipmakers set the tone, while housing and lithium...

Via Chartmill

Topics Artificial Intelligence

Earnings Scheduled For July 29, 2025 ↗

July 29, 2025

Via Benzinga

uniQure Earnings Preview ↗

July 28, 2025

Via Benzinga

Alibaba, Intel, Uniqure, Tesla And Opendoor: Why These 5 Stocks Are On Investors' Radars Today ↗

September 24, 2025

U.S. stocks slipped on Wednesday, with the Nasdaq losing more than 75 points, or 0.3%, to close at 22,497.85.

Via Benzinga

UniQure Stock Hits 5-Year High As Analysts Hail Huntington’s Therapy Data — Retail Spots ‘Diamond In Rough Of Biotech’ ↗

September 24, 2025

UniQure said the high-dose of its AMT-130 therapy slowed Huntington’s disease progression by up to 75% over three years and plans to seek FDA approval in early 2026.

Via Stocktwits

uniQure Announces $200 Million Proposed Public Offering

September 24, 2025

From uniQure Inc.

Via GlobeNewswire

Nasdaq Down Over 100 Points; US Crude Oil Stocks Fall ↗

September 24, 2025

Via Benzinga

What's Going On With UniQure Stock Wednesday? ↗

September 24, 2025

UniQure N.V. (NASDAQ:QURE) shares are trading higher Wednesday after the company announced positive topline results from Phase I/II study of AMT-130 in patients with Huntington's Disease.

Via Benzinga

Lithium Americas, Alibaba, uniQure, IREN, Cidara: Stocks Making The Biggest Moves Today ↗

September 24, 2025

Via Stocktwits

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

September 24, 2025

Via Benzinga

A Cure For Huntington's Disease? UniQure Launches More Than 240%. ↗

September 24, 2025

The company's gene therapy slowed disease progression by 75% over three years.

Via Investor's Business Daily

uniQure Stock Doubles On Promising Data From Huntington's Disease Trial ↗

September 24, 2025

UniQure's AMT-130 gene therapy slowed Huntington's disease progression in a Phase 1/2 trial, supported by new $175 million financing for launch readiness.

Via Benzinga

uniQure Stock Rises Pre-Market After Investigational Huntington’s Disease Drug Slows Disease In Trial ↗

September 24, 2025

The company stated that high-dose AMT-130 demonstrated 75% disease slowing at 36 months, as measured by the composite Unified Huntington's Disease Rating Scale.

Via Stocktwits

uniQure Announces Refinancing of Existing $50 Million Debt and Securing Up to an Additional $125 Million in Non-Dilutive Funding

September 24, 2025

From uniQure Inc.

Via GlobeNewswire

uniQure Announces Positive Topline Results from Pivotal Phase I/II Study of AMT-130 in Patients with Huntington’s Disease

September 24, 2025

From uniQure Inc.

Via GlobeNewswire

uniQure's Investigational Gene Therapy Shows Promising Efficacy With Manageable Safety Risks For Fabry Disease ↗

September 05, 2025

uniQure's early AMT-191 trial data in Fabry disease showed strong enzyme activity, manageable safety, and patient independence from enzyme replacement therapy.

Via Benzinga

uniQure Announces Initial AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease

September 05, 2025

From uniQure Inc.

Via GlobeNewswire

FDA Outlines Process To Speed Up Rare Disease Therapy Approvals ↗

September 04, 2025

FDA launches Rare Disease Evidence Principles to guide therapy reviews, offering new pathways for approval while raising questions on development impact.

Via Benzinga

Vinay Prasad's Comeback To FDA Sparks Debate Over Regulatory Direction ↗

August 11, 2025

Vinay Prasad returns as FDA's CBER director after brief exit, raising questions on rare disease drug approvals and mRNA vaccine oversight.

Via Benzinga

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday? ↗

July 30, 2025

Vinay Prasad exits FDA's biologics division following pressure over Sarepta's Elevidys approval and regulatory controversies.

Via Benzinga

uniQure Narrows Loss in Fiscal Q2 ↗

July 29, 2025

Via The Motley Fool

uniQure NV (NASDAQ:QURE) Posts Q2 2025 Earnings: EPS Beat Offsets Revenue Miss as Regulatory Progress Boosts Shares ↗

July 29, 2025

uniQure NV reports mixed Q2 2025 results with revenue missing estimates but EPS beating forecasts. Shares rise on regulatory progress for Huntington's gene therapy AMT-130.

Via Chartmill

uniQure Announces Second Quarter 2025 Financial Results and Highlights of Recent Company Progress

July 29, 2025

From uniQure Inc.

Via GlobeNewswire

uniQure to Announce Second Quarter 2025 Financial Results

July 22, 2025

uniQure to host earnings call on Tuesday, July 29, 2025 at 8:30 a.m. ET

From uniQure Inc.

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.